Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy

Authors

G A Amos Burke
Auke Beishuizen
Deepa Bhojwani
Birgit Burkhardt
Véronique Minard-Colin
Robin E. Norris
Edita Kabickova
F Guclu Pinarli
Nurdan Tacyildiz
Angela Howes
Jan de Jong
Grace Liu
Kerri Nottage
Mariya Salman
Xavier Woot de Trixhe
Mitchell Cairo, New York Medical CollegeFollow

Journal Title

Leukemia

First Page

2271

Last Page

2275

Document Type

Article

Publication Date

8-2020

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R. E., Kabickova, E., Pinarli, F. G., Tacyildiz, N., Howes, A., de Jong, J., Liu, G., Nottage, K., Salman, M., de Trixhe, X. W., & Cairo, M. (2020). Ibrutinib Plus CIT for R/R Mature B-NHL in Children (SPARKLE Trial): Initial Safety, Pharmacokinetics, and Efficacy. Leukemia, 34 (8), 2271-2275. https://doi.org/10.1038/s41375-020-0749-5